Drug intelligence / Profile preview

fraxinus americana pollen extract

Development stage
Unknown
Lead developer
ALK Abelló
Modality
Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
Administration
Percutaneous, Intradermal, Subcutaneous
01

Overview

Fraxinus americana pollen is an allergenic extract derived from the pollen of the white ash tree (Fraxinus americana). It is a biologic product used for both diagnosing and treating allergies to this specific pollen. For diagnosis, it is administered via skin testing (percutaneous or intradermal). For treatment, it is used in immunotherapy (also known as hyposensitization or allergy shots) administered subcutaneously. The therapy works by gradually exposing the patient's immune system to the allergen, which induces immune tolerance. This process involves a shift in the immune response, including an increase in allergen-specific Immunoglobulin G (IgG) antibodies and a decrease in specific Immunoglobulin E (IgE) production, ultimately reducing the severity of allergic symptoms upon natural exposure. The product is marketed by companies such as ALK-Abello, Inc. and Greer Laboratories, Inc. as a non-standardized allergenic extract.

Brand names
Fraxinus Americana PollenAsh WhiteCENTER-AL
Other names
white ash pollenFraxinus biltmoreana pollen

Beyond the preview

Go deeper on fraxinus americana pollen extract.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on fraxinus americana pollen extract.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call